Evidence map›Paper›PMID 34171218›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2021

The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat.

Roderick Clark, Miran Kenk, Kristen McAlpine, Emily Thain, Kirsten M Farncombe, Colin C Pritchard, Robert Nussbaum, Alexander W Wyatt, Johann de Bono, Danny Vesprini and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 3 countries.

Roderick ClarkDivision of Urology, University Health Network, Toronto, ON, Canada.
Miran KenkPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Kristen McAlpineDivision of Urology, University Health Network, Toronto, ON, Canada.
Emily ThainFamilial Cancer Clinic, University Health Network, Toronto, ON, Canada.
Kirsten M FarncombeToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
Robert NussbaumInvitae Corporation, San Francisco, CA, United States.
Alexander W WyattDepartment of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
Johann de BonoInstitute of Cancer Research, Royal Marsden Hospital, London, United Kingdom.
Danny VespriniDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Yvonne BombardLi Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada.
Justin LorentzGenetics and High Risk Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Steven NarodFamilial Breast Cancer Research Unit, Women's College Research Institute, Toronto, ON, Canada.
Raymond KimDepartment of Medical Oncology, University Health Network, Toronto, ON, Canada.
Neil FleshnerDivision of Urology, University Health Network, Toronto, ON, Canada.
University Health Network · CAHealth Sciences Centre · CAInstitute of Cancer Research · GBInvitae (United States) · USSt. Michael's Hospital · CAToronto General Hospital · CAUniversity of British Columbia · CAUniversity of Washington · USWomen's College Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a significant cause of cancer mortality. It has been well-established that certain germline pathogenic variants confer both an increased risk of being diagnosed with prostate cancer and dying of prostate cancer.1 There are exciting developments in both the availability of genetic testing and opportunities for improved treatment of patients.On August 19, 2020, the Princess Margaret Cancer Centre in Toronto, Ontario, hosted a virtual retreat, bringing together international experts in urology, medical oncology, radiation oncology, medical genetics, and translational research, as well as a patient representative. We are pleased to provide this manuscript as a review of those proceedings for Canadian clinicians.We highlighted several needs for future research and policy action based on this meeting:Increased access to funding for germline testing for the common genetic disorders associated with increased risk of prostate cancer.More research into identifying genetic factors influencing risk stratification, treatment response, and outcomes of prostate cancer within Canadian populations at higher genetic risk for prostate cancer.Added awareness about genetic risk factors among the Canadian public.Development of patient-specific and reported outcomes research in tailored care for patients at increased genetic risk of prostate cancer.Creation of multidisciplinary clinics that specialize in tailored care for patients at increased genetic risk of prostate cancer.

Identifiers

PMID34171218
PMCPMC8631832
OpenAlexW3174824255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.